ALNY
Alnylam Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Nasdaq-100Russell 3000
$165.00Close
$21.8BMarket cap
$165.00 – $473.2952-week range
Late-januaryNext report · estimated
Highlights
Strengths
- Earnings growing EPS +637% year on year
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 4 · weaker than 96% of stocks over 12 months
- Far from its high 65% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
65%
1wk
down 26.3%
price change
1mo
down 33.1%
price change
12-month return
down 63%
market up 11% ·
its own down 77%
F-score
6 / 9
Mixed
Altman Z
2.95
Moderate risk
P/E
69.6×
price / earnings
PEG
—
P/E / EPS growth
P/B
27.7×
price / book
Earnings yield
up 2.5%
EBIT / enterprise value
Cheaper than
27%
of the market · expensive
Revenue growth
up 65%
year on year
EPS growth
up 637%
latest quarter
Sales growth
up 17%
latest quarter · -50 pts
ROE
up 73%
return on equity
Free cash margin
up 13%
$465.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-3.0×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- assets working harder
Repair signals
- FCF turned positive ($-43M → $465M)
Trade setup
ATR%
7.7%
$12.70 a day · 2×ATR $139.61
RS
4 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
4.2×
vs 50-day average
Up/down volume
0.72
50 sessions
Implied move
—
no scheduled report
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.4% over the year, from 129m to 132m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 86.4% to 81.8%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 29, 2026
Last shock
Jul 30, 2026-28% in one session6.0× volumeon results-20% since
Financials
- Gross 82%
- Net 8%
- Free cash 13%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $492.9M | $844.3M | $1.0B | $1.8B | $2.2B | $3.7B |
| Gross margin | 85% | 86% | 86% | 85% | 86% | 82% |
| Operating income | -$828.4M | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Net income | -$858.3M | -$852.8M | -$1.1B | -$440.2M | -$278.2M | $313.7M |
| Net margin | -174% | -101% | -109% | -24% | -12% | 8% |
| Earnings per share | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 |
| Free cash flow | -$685.3M | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
| Free cash margin | -139% | -85% | -59% | 2% | -2% | 13% |
| Cash | $496.6M | $820.0M | $866.4M | $812.7M | $966.4M | $1.7B |
| Long-term debt | $191.3M | $675.7M | — | — | — | — |
| Shareholders' equity | $1.0B | $588.2M | -$158.2M | -$220.6M | $67.1M | $789.2M |
| Shares outstanding | 116.43m | 120.18m | 123.92m | 125.79m | 129.29m | 132.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Jul 30, 2026 | Results ↗ |
| May 27, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 30, 2026 | Results ↗ |
| Mar 4, 2026 | Director or officer change ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Dec 11, 2025 | Other events ↗ |
| Dec 3, 2025 | Director or officer change ↗ |
| Oct 30, 2025 | Results ↗ |
| Oct 3, 2025 | Material agreement · New obligation ↗ |
| Sep 12, 2025 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |